DSP-0038

DSP-0038 is a serotonin receptor modulator that acts as a 5-HT2A receptor antagonist and 5-HT1A receptor agonist. It is under development for psychosis related to Alzheimer's disease. The drug was developed using artificial intelligence that enabled it to proceed from discovery to Phase I trial in one year, compared to an industry average of 4–6 years.